|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Treatment Intensification in Metastatic Castrate-Sensitive Prostate Cancer
|
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
In this discussion, Zachary Klaassen and Christopher Wallis discuss treatment intensification in metastatic castrate-sensitive prostate cancer (mCSPC).
|
|
|
|
|
|
|
|
|
|
|
|
The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
|
Russell Szmulewitz, MD
Russell Szmulewitz joins Charles Ryan in a discussion highlighting three abstracts in the metastatic hormone-sensitive prostate cancer treatment landscape when discussing treatment intensification.
|
|
|
|
|
|
|
|
|
|
|
|
mHSPC Network Meta-Analysis on the Use of Intensified Treatments
|
|
Fred Saad, MD, FRCS
|
| Fred Saad joins Alicia Morgans to discuss his recently published network meta-analysis on treatments for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
|
|
|
|
|
|
|
|
|
|
|
|
|
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race
|
|
Stephen J. Freedland, MD
|
| Stephen Freedland discusses a retrospective analysis of the Medicare database from January 2009-Dec 2018 on the real-world use of advanced therapies over time and the use of patterns among racial minorities that are often under-represented in clinical trials.
|
|
|
|
|
|
|
|
|
|
|
|
| Real-World Utilization of Advanced Therapies and Racial Disparity Among Patients with Metastatic Castration-Sensitive Prostate Cancer: A Medicare Database Analysis
|
| Stephen J. Freedland, MD
|
| Stephen Freedland presents the results of an analysis of Medicare data regarding real-world utilization of these agents in men with mCSPC. Based on this large and nationally representative sample of men with mCSPC patients, treatment intensification was uncommonly used with some, but not dramatic, an improvement over time.
|
|
|
|
|
|
|
|
|
|
|
| Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Cases - Synchronous High Volume mHSPC
|
| Rashid Sayyid, MD, MSc, Christopher Wallis, MD, Ph.D., & Zachary Klaassen, MD, MSc
|
| The addition of docetaxel and/or androgen receptor-axis targeted (ARAT) agents to standard androgen deprivation therapy (ADT), in the form of doublet and triplet treatment strategies, has demonstrated overall survival benefits in this cohort of patients. As such, these drug combinations have changed the standard of care approaches in these men.
|
|
|
|
|
|
| Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Cases - Synchronous Low Volume mHSPC |
| Rashid Sayyid, MD, MSc, Christopher Wallis, MD, Ph.D., & Zachary Klaassen, MD, MSc
|
| The incidence of metastatic prostate cancer at diagnosis ranges from ~5-50%, with significant geographic differences as previously described.2 Such patients are defined as having de novo or synchronous mHSPC. Additionally, there exits a subset of men initially diagnosed with non-metastatic disease, many of whom have received prior definitive local treatment, who will have progression to a metastatic state prior to development of castration resistance.
|
|
|
|
|
|
| Making Sense of the Intensified mHSPC Landscape - Discussion
|
| Russell Z. Szmulewitz, MD
|
| Russell Szmulewitz provides a presentation on making sense of the intensified mHSPC landscape. Dr. Szmulewitz notes that intensification means building on ADT and highlights important clinical trials in the mHSPC space.
|
|
|
|
|
|
| Future Directions in Systemic Treatment of Metastatic Hormone-Sensitive Prostate Cancer - Beyond the Abstract
|
| Arun Azad, Kenneth Chen, & Louise Kostos
|
| The treatment of metastatic prostate cancer has seen a paradigm shift, particularly in the management of metastatic hormone sensitive prostate cancer (mHSPC). The developments come not only on the fronts of systemic agents but also in the area of therapy to primary tumour and metastases.
|
|
|
|
|
|
|
|
|
|
|
|
